Hew KE, Miller PC, El-Ashry D, Sun J, Besser AH, Ince TA, Gu M, Wei Z, Zhang G, Brafford P, Gao W, Lu Y, Mills GB, Slingerland JM, Simpkins F: MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer. Clin Cancer Res 22(4):935-47 : 2016.
George E, Kim H, Tanyi J, Ragland R, Brown E, Zhang R, Brafford P, Sproesser K, Beqiri M, Vultur A, Krepler C, Lee R, Weis B, Nathanson K, Lu Y, Mills G, Makvandi M, Mach R, Morgan M, Herlyn M, Simpkins F: A novel orthotopic ovarian patient derived xenograft model platform to investigate novel therapies for BRCA deficient ovarian cancers. Poster, AACR, New Orleans, LA, : 2016.
Zhang X, Haggerty AF, Brown JC, Giuntoli R 2nd, Lin L, Simpkins F, Dean LT, Ko E, Morgan MA, Schmitz KH: The prescription or proscription of exercise in endometrial cancer care. Gynecol Oncol 139(1):155-9 : 2015.
Kim H, George E, Brown E, Zhang R, Krepler C, Tanyi J, Lee R, Morgan MA, Herlyn M, Simpkins, F: Targeting the ATR/CHK1 axis in BRCA1/2 mutant ovarian cancer using an orthotopic patient-derived xenograft (PDX) model. Poster, AACR, Orlando, FL, : 2015.
Chen J, Solomides C, Parekh H, Simpkins F, Simpkins H: Cisplatin resistance in human cervical, ovarian and lung cancer cells. Cancer Chemother Pharmacol 75(6):1217-27 : 2015.
Garcia-Soto A, McKenzie N, Portelance L, Castillo R, Pearson M, Hu J, Lucci JA 3rd, Lin L, Simpkins F: Phase I trial of nelfinavir added to cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer. Poster and published for ASCO. J Clin Oncol 33 (suppl; abstr TPS5619) : 2015.
Simpkins F, Drake R, Escobar PF, Nutter B, Rasool N2, Rose PG: A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA). Gynecol Oncol 136(2):240-5 : 2015.
Cui H, He Y, Krepler C, Tanyi J, Morgan MA, Burger RA, Kim S, Ko E, Ince T, Herlyn M, Simpkins F: A true orthotopic ovarian cancer patient-derived xenograft (PDX) model. Poster and published for AACR, Philadelphia, PA, Cancer Res 75; 3223 : 2015.
Hew K, Miller P, Sun J, Wei Z, Zhang G, Lu Y, Mills G, Slingerland J, El-Ashry D, Simpkins F: MEK inhibition reverses antiestrogen resistance in ovarian cancer (OVCA) via alteration of cell cycle pathways and MAPK/estrogen regulated gene expression. Oral presentation and published, AACR Meeting, Marsha Rivkin Center for Ovarian Cancer Research Symposia, Seattle WA Clin Cancer Res 21; AS31 : 2014.
Simpkins F, Hew K, Azzam D, Wei Z, Zhang G, Sun J, Zhang D, Jang K, Liu W, Lu Y, Mills G, Tan I, Slingerland J: Combined Src and MEK inhibition decreases ovarian cancer (OVCA) cell growth, tumorigenicity and aldehyde dehydrogenase positive tumor-initiating-cells. Poster and published for the AACR Meeting, Marsha Rivkin Center for Ovarian Cancer Research Symposia, Seattle WA, Clin Cancer Res 21; POSTER-THER-1431 : 2014.